Cite
MLA Citation
Mohamed Attauabi et al.. “Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.” Scandinavian journal of gastroenterology, vol. 56, 2021, pp. 1040–1048. http://access.bl.uk/ark:/81055/vdc_100139924751.0x000058